Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.37 |
| ▸ | WNT3A | P56704 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232700 | 1.00 | CTSA (0.38) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL6924244 | 1.00 | CTSA (0.38) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL14034081 | 0.78 | KDM4E (0.35) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL30139581 | 0.77 | ADRA2A (0.37) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL14394979 | 0.77 | ADRA2A (0.37) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL5222559 | 0.77 | ADRA2A (0.37) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL15863495 | 0.76 | ALDH1A1 (0.47) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL20385462 | 0.74 | MGLL (0.42) | CTSACTNNB1WNT3AKDM4EL3MBTL1 | |
| SCHEMBL29335085 | 0.73 | NAPRT (0.53) | KDM4EL3MBTL1MPIMAPTALDH1A1 | |
| SCHEMBL6069313 | 0.73 | NAPRT (0.53) | KDM4EL3MBTL1MPIMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| EP-3652178-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-05-20 | — | — | EP | disclosed |
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| US-8916584-B2 | Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2533642-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011100614-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | CTSA 4048/4885CTNNB1 2397/4885WNT3A 2537/4885 |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | CTSA 4048/4885CTNNB1 2397/4885WNT3A 2537/4885 |
| US-10975095-B2 | — | CYP1B1, UGT1A1, CYP4B1 | CTSA 2955/4885CTNNB1 1309/4885WNT3A 2159/4885 |
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRIK4, GRM4, GRIA4 | CTSA 2719/4885CTNNB1 4765/4885WNT3A 4681/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | CTSA 4048/4885CTNNB1 2397/4885WNT3A 2537/4885 |
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | CTSA 1940/4885CTNNB1 1156/4885WNT3A 242/4885 |
| US-20240300974-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | CTSA 4048/4885CTNNB1 2397/4885WNT3A 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.